GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma

Pallavi Madhiraju- November 28, 2023 0

GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More

Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma

Pallavi Madhiraju- May 28, 2023 0

Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based ... Read More

Zydus Lifesciences gets FDA approval for Bortezomib for Injection

pallavi123- May 3, 2022 0

Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for ... Read More